We were very excited to learn of this trial, a much-needed step toward reducing deaths from tuberculosis. We applaud Gates and Wellcome for this sizable commitment of resources, which is, as Nick points out, necessary to gain adequate information about the vaccine’s efficacy, but beyond the reach of most funders.
We have investigated TB-related funding opportunities, and we remain very open to funding either programs or research. However, we have several significant uncertainties about the programs we’ve explored so far and have not yet funded any at scale.
We are working on a report summarizing the evidence for mass TB screen-and-treat programs, which will provide more detail on our views specific to that type of program.
Hi, Hakon,
We were very excited to learn of this trial, a much-needed step toward reducing deaths from tuberculosis. We applaud Gates and Wellcome for this sizable commitment of resources, which is, as Nick points out, necessary to gain adequate information about the vaccine’s efficacy, but beyond the reach of most funders.
We have investigated TB-related funding opportunities, and we remain very open to funding either programs or research. However, we have several significant uncertainties about the programs we’ve explored so far and have not yet funded any at scale.
We are working on a report summarizing the evidence for mass TB screen-and-treat programs, which will provide more detail on our views specific to that type of program.
Best, Miranda
Fantastic, thanks for the update Miranda!